Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone in Patients With Locally/Regionally Advanced/Recurrent Melanoma: A Randomized Efficacy, Safety and Biomarker Study
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Biomarker; Therapeutic Use
- 18 Sep 2017 Status changed from discontinued to withdrawn prior to enrolment.
- 10 Jun 2017 Biomarkers information updated
- 01 May 2017 Status changed from recruiting to discontinued.